Circulating Extracellular Vesicles Are Strongly Associated With Cardiovascular Risk Markers.
blood lipids
blood pressure
cardiovascular risk markers
extracellular vesicles
thrombin
Journal
Frontiers in cardiovascular medicine
ISSN: 2297-055X
Titre abrégé: Front Cardiovasc Med
Pays: Switzerland
ID NLM: 101653388
Informations de publication
Date de publication:
2022
2022
Historique:
received:
30
03
2022
accepted:
05
05
2022
entrez:
13
6
2022
pubmed:
14
6
2022
medline:
14
6
2022
Statut:
epublish
Résumé
Extracellular vesicles (EVs) are submicron membrane-bound vesicles released from various cells, which are emerging as a potential novel biomarker in cardiovascular diseases (CVDs) due to their procoagulatory and prothrombotic properties. However, there is little information about the relationships between circulating EVs and conventional and thrombogenic risk markers of CVDs. To investigate the relationships between circulating EVs, conventional cardiovascular risk markers and thrombogenic markers in subjects with moderate risk of CVDs. Subjects ( Circulating EV numbers were positively associated with body mass index, blood pressure, plasma triacylglycerol concentration and overall CVD risk. Higher circulating EV numbers were also associated with increased thrombin generation and enhanced clot formation, and EVs isolated from subjects with moderate CVD risk promoted thrombin generation Circulating EVs were strongly associated with both conventional and thrombogenic risk markers of CVDs, and also with overall CVD risk, highlighting a potentially important role for EVs in CVDs.
Sections du résumé
Background
UNASSIGNED
Extracellular vesicles (EVs) are submicron membrane-bound vesicles released from various cells, which are emerging as a potential novel biomarker in cardiovascular diseases (CVDs) due to their procoagulatory and prothrombotic properties. However, there is little information about the relationships between circulating EVs and conventional and thrombogenic risk markers of CVDs.
Objective
UNASSIGNED
To investigate the relationships between circulating EVs, conventional cardiovascular risk markers and thrombogenic markers in subjects with moderate risk of CVDs.
Design
UNASSIGNED
Subjects (
Results
UNASSIGNED
Circulating EV numbers were positively associated with body mass index, blood pressure, plasma triacylglycerol concentration and overall CVD risk. Higher circulating EV numbers were also associated with increased thrombin generation and enhanced clot formation, and EVs isolated from subjects with moderate CVD risk promoted thrombin generation
Conclusion
UNASSIGNED
Circulating EVs were strongly associated with both conventional and thrombogenic risk markers of CVDs, and also with overall CVD risk, highlighting a potentially important role for EVs in CVDs.
Identifiants
pubmed: 35694679
doi: 10.3389/fcvm.2022.907457
pmc: PMC9178174
doi:
Types de publication
Journal Article
Langues
eng
Pagination
907457Informations de copyright
Copyright © 2022 Zhou, Bozbas, Allen-Redpath and Yaqoob.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
J Extracell Vesicles. 2017 Jul 19;6(1):1344087
pubmed: 28804597
J Thromb Haemost. 2014 May;12(5):614-27
pubmed: 24618123
J Thromb Thrombolysis. 2017 Feb;43(2):224-232
pubmed: 28074413
J Thromb Haemost. 2010 Dec;8(12):2596-607
pubmed: 20880256
Nanomedicine. 2011 Dec;7(6):780-8
pubmed: 21601655
Thromb Res. 2014 Nov;134(5):963-9
pubmed: 25213709
Eur Heart J. 2006 Apr;27(7):817-23
pubmed: 16434416
Blood. 2006 May 1;107(9):3537-45
pubmed: 16449527
Diabetes Metab Syndr Obes. 2019 Apr 12;12:485-493
pubmed: 31043798
Blood Rev. 2012 Sep;26(5):197-203
pubmed: 22762893
Arterioscler Thromb Vasc Biol. 2006 Dec;26(12):2775-80
pubmed: 17038634
J Atheroscler Thromb. 2010 Apr 30;17(4):342-9
pubmed: 20379056
Thromb Res. 2000 May 15;98(4):257-68
pubmed: 10822072
JAMA. 2003 Aug 20;290(7):898-904
pubmed: 12928466
PLoS One. 2012;7(4):e35713
pubmed: 22563392
Eur Heart J. 2014 Nov 7;35(42):2972-9
pubmed: 24742886
Am Heart J. 2003 Jun;145(6):962-70
pubmed: 12796750
Nutrients. 2014 Mar 24;6(3):1236-50
pubmed: 24667131
Arch Intern Med. 2007 Mar 26;167(6):573-9
pubmed: 17389288
Cytometry A. 2010 Jun;77(6):502-14
pubmed: 20235276
Hypertension. 2003 Feb;41(2):211-7
pubmed: 12574084
Cardiovasc Res. 2016 Jun 1;110(3):319-30
pubmed: 26980205
Thromb Haemost. 2014 Nov;112(5):860-7
pubmed: 25231258
Exp Lung Res. 2013 May-Jun;39(4-5):155-61
pubmed: 23550836
Circulation. 2004 Dec 7;110(23):3599-603
pubmed: 15569844
Lancet. 2012 Dec 15;380(9859):2095-128
pubmed: 23245604
Thromb Haemost. 2008 Nov;100(5):878-85
pubmed: 18989533
Cytometry B Clin Cytom. 2011 Jan;80(1):57-63
pubmed: 20632415
J Clin Invest. 1999 Jul;104(1):93-102
pubmed: 10393703
Arch Med Sci. 2017 Aug;13(5):1049-1056
pubmed: 28883845
Sci Rep. 2018 Nov 21;8(1):17216
pubmed: 30464183
Thromb Haemost. 2001 Apr;85(4):639-46
pubmed: 11341498
Blood. 2007 Oct 1;110(7):2432-9
pubmed: 17606760
Atherosclerosis. 2000 Oct;152(2):407-14
pubmed: 10998469
Cryobiology. 2002 Apr;44(2):179-88
pubmed: 12151273
Obesity (Silver Spring). 2013 Nov;21(11):2236-43
pubmed: 23512861
J Extracell Vesicles. 2014 Sep 30;3:
pubmed: 25317277
Sci Rep. 2018 Jul 3;8(1):9987
pubmed: 29968812
Mol Metab. 2018 Dec;18:134-142
pubmed: 30473096
Blood. 2010 Mar 11;115(10):2048-56
pubmed: 19996088
J Extracell Vesicles. 2017 Apr 4;6(1):1308779
pubmed: 28473885
J Cell Biol. 2013 Feb 18;200(4):373-83
pubmed: 23420871
Thromb Haemost. 2012 Dec;108(6):1208-19
pubmed: 23138460
Maturitas. 2014 Jul;78(3):179-83
pubmed: 24846805
J Investig Med. 2014 Feb;62(2):345-9
pubmed: 24402298
J Thromb Haemost. 2006 Jun;4(6):1296-302
pubmed: 16706974
Heart. 2006 Dec;92(12):1752-9
pubmed: 16621883
J Thromb Thrombolysis. 2011 Feb;31(2):173-9
pubmed: 20680403
Exp Physiol. 2018 Nov;103(11):1560-1570
pubmed: 30062787
Bioscience. 2015 Aug 1;65(8):783-797
pubmed: 26955082
Circulation. 2011 May 24;123(20):2292-333
pubmed: 21502576
Hypertens Res. 2011 Jun;34(6):665-73
pubmed: 21512515
Hypertension. 2003 Jul;42(1):1-7
pubmed: 12782643
J Extracell Vesicles. 2017 Apr 10;6(1):1305677
pubmed: 28473884
Am J Clin Nutr. 2000 Nov;72(5 Suppl):1307S-1315S
pubmed: 11063473
J Thromb Haemost. 2012 Jul;10(7):1355-62
pubmed: 22537188
J Thromb Haemost. 2011 Jun;9(6):1216-24
pubmed: 21481178
J Exp Med. 2003 Jun 2;197(11):1585-98
pubmed: 12782720
Circulation. 2001 Mar 6;103(9):1245-9
pubmed: 11238268
Blood Adv. 2018 May 22;2(10):1054-1065
pubmed: 29752284
Sci Rep. 2017 Jul 26;7(1):6522
pubmed: 28747771
Int J Mol Sci. 2019 Jun 11;20(11):
pubmed: 31212641
Cytokine Growth Factor Rev. 2018 Dec;44:38-50
pubmed: 30340925
Acta Cardiol. 2017 Feb;72(1):2-8
pubmed: 28597734
Am J Public Health Nations Health. 1951 Mar;41(3):279-81
pubmed: 14819398
J Thromb Thrombolysis. 2021 Apr;51(3):711-719
pubmed: 33247807
Thromb Haemost. 2010 May;103(5):1044-52
pubmed: 20390225
JAMA. 2011 Nov 16;306(19):2120-7
pubmed: 22089719
Blood Coagul Fibrinolysis. 2017 Jul;28(5):373-382
pubmed: 27926582
N Engl J Med. 2008 May 15;358(20):2107-16
pubmed: 18480203
Biochemistry (Mosc). 2016 Feb;81(2):114-21
pubmed: 27260391
J Thromb Haemost. 2005 Jun;3(6):1301-8
pubmed: 15946221
Eur Heart J. 2011 Aug;32(16):2034-41
pubmed: 21186238
J Proteomics. 2010 Sep 10;73(10):1907-20
pubmed: 20601276
Circ Res. 2017 May 12;120(10):1649-1657
pubmed: 28495995
J Extracell Vesicles. 2016 Oct 31;5:32945
pubmed: 27802845
Arterioscler Thromb Vasc Biol. 2008 Dec;28(12):2247-54
pubmed: 18974382
BMJ. 2008 Jun 28;336(7659):1475-82
pubmed: 18573856
J Clin Pharmacol. 2013 Dec;53(12):1228-39
pubmed: 24030923
Am J Epidemiol. 1986 Dec;124(6):903-15
pubmed: 3776973
J Thromb Haemost. 2005 Dec;3(12):2754-63
pubmed: 16359513
Blood. 2009 Nov 26;114(23):4886-96
pubmed: 19797520